Treatment of Lambert-Eaton paraneoplastic syndrome;Traitement du syndrome de Lambert-Eaton paraneoplasique

Revue de Pneumologie Clinique

Volumn 54, Issue 2, 1998, Pages 65-70

  Courau, E ^a   Westeel, V ^a   Jacoulet, P ^a   Depierre, A ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Lambert Eaton syndrome; Paraneoplastic syndrome; Small cell bronchogenic cancer; Treatment

Indexed keywords

AUTOIMMUNITY; EATON LAMBERT SYNDROME; HUMAN; HYPOREFLEXIA; IMMUNOMODULATION; LUNG SMALL CELL CANCER; MUSCLE FATIGUE; NEUROMUSCULAR SYNAPSE; PARANEOPLASTIC SYNDROME; REVIEW; VOLUNTARY MOVEMENT; XEROSTOMIA;

CHOLINERGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LAMBERT-EATON MYASTHENIC SYNDROME; PARANEOPLASTIC SYNDROMES;

EID: 0031869636     PISSN: 00325821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Lambert E. H., Eaton L. M., Rooke E. D. : Defect of neuromuscular condition associated with malignant neoplasm. Am. J. Physiol., 1956, 187, 612-3.
2. Lambert E. H., Rooke E. D. : Myasthenic state and lung cancer. In : Brain R., Norris F. H. Editors : The remote effects of cancer on the nervous system. New York : Grune and Statton, 1965, pp. 67-80.
3. Bady B., Truffer A., Brechard M., Brunon M., Chauplannaz G., Clavelou P., Flocard F., Gouttard M., Robert H., Soichot P., Vial C. : Données électrophysiologiques dans les syndromes myasthéniques de type Lambert-Eaton. A propos de 23 cas. Neurophysiol. Clin., 1992, 22, 27-39.
4. Lang B., Newsom-Davis J., Wray D., Murray N. : Autoimmune aetilosy for myasthenic (Eaton-Lambert) svndrome. Lancet, 1981, 2, 224-6.
5. Fukuoka T., Engel A. G., Lang B., Newsom-Davis J., Prior C., Wray D. W. : Lambert-Eaton myasthenic syndrome : early morphological effects of IgG on the presynaptic membrane active zones. Ann. Neurol., 1987, 22, 193-9.
6. Zenone T., Bady B., Souquet P. J., Bernard J. P. : Le syndrome de Lambert-Eaton. Rev. Mal. Resp., 1992, 9, 483-90.
7. Eymard B. : Myasthénie auto-immune et syndrome myasthénique de Lambert-Eaton. Ann. Méd. Interne, 1989, 140, 462-6.
8. Chalk C. H., Murray N. M. F., Newson-Davis J., O'Neill J. H., Spiro S. G. : Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small cell lung carcinoma. Neurology, 1990, 40, 1552-6.
9. Bady B., Vial C., Chauplannaz G. : Syndrome de Lambert-Eaton : étude clinique et électrophysiologique de 18 cas associés à un cancer du poumon. Rev. Neurol., 1992, 148, 513-9.
10. Ferroir J. P., Hervier-Caen C., Reignier A., Nicolle M. H., Guillard A. : Rémission d'un syndrome de Lambert-Eaton pendant 10 ans sans récidive à l'autopsie. Rev. Neurol., 1989, 145, 851-2.
11. Clamon G. H., Evans W. K., Shepherd F. A., Humphrey J. G. : Myasthenic syndrome and small cell cancer of the lung : variable response to antineoplastic therapy. Arch. Intern. Med., 1984, 144, 999-1000.
12. Ongerboer de Visser B. W., Boven E., Ten Bokkel Huinink W. B. : Eaton-Lambert syndrome : electrophysiological normalization during chemotherapy. Clin. Neurol. Neurosurg., 1979, 81, 235-40.
13. Louarn F., Mas J. L., Verroust J. : Syndrome de Lambert-Eaton : evolution favorable sous traitement exclusif de la néoplasie associée Nouv Presse Méd, 1982, 11, 208.
14. Berglund S., Eriksson M., Von Eyben F. E., Hellekant C., Mattson W. : Remission by chemotherapy of the Eaton-Lambert myasthenic syndrorne in a patient with small cell bronchogenic carcinoma. Acta Med. Scand., 1982, 212, 429-33.
15. Jablecki C. : Lambert-Eaton myasthenic syndrome. Muscle & Nerve, 1984, 7, 250-7.
16. Sanders D. B., Kim Y. I., Howard J. F., Allen Goetsh C. : Eaton-Lambert syndrome : a clinical and electrophysiological study of a patient treated with 4-aminopyridine. J. Neurol. Neurosurg. Psy., 1980, 43, 978-85.
17. Lundh H., Nilson O., Rosén I. : 4-aminopyridine : a new drug tested in the treatment of Eaton-Lambert syndrome. J. Neurol. Neurosurg. Psy., 1977, 40, 1109-12.
18. Kartz B., Miledi R. : Estimates of quantal content during «Chemical potentiation» of transmitter release. Proc. R. Soc. Lond. (Biol.), 1979, 205, 369-78.
19. Gordon Smith A., Wald J. : Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. Neurology, 1996, 46, 1143-6.
20. Sanders D. B. : Lambert-Eaton syndrome : clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann. Neurol., 1995, 37 (S1), S63-73.
21. Oh S. J., Kim K. W. : Guanidine hydrochloride in the Eaton-Lambert syndrome. Neurology, 1973, 23, 1084-90.
22. Cherington M. : Guanidine and germine in Eaton-Lambert syndrome. Neurology, 1976, 26, 944-6.
23. Molgó J., Gugliemli J. M. : 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome. Pflügers Arc-Eur. J. Physiol., 1996, 431 (suppl), R295-6.
24. Murray N. M. F., Newsom-Davis J. : Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology, 1981, 31, 265-71.
25. Lundh H., Nilson O., Rosén I., Johansson S. : Practical aspects of 3,4-diaminopyridine treatment of Lambert-Eaton myasthenic syndrome. Acta Neurol. Scand., 1993, 88, 136-40.
26. McEvoy K. M., Windebank A. J., Daube J. R., Low P. A. : 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N. Engl. J. Med., 1989, 321, 1567-71.
27. Lundh H., Nilson O., Rosén I. : Treatment of Lambert-Eaton syndrome. 3,4-diaminopyridine and pyridostigmine. Neurology, 1984, 34, 1324-30.
28. Molgó J., Lundh H., Thesleff S. : Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of PH changes. Eur. S. Pharmacol., 1980, 61, 25-34.
29. Ingram D. A., Davis G. R., Schwartz M. S., Traub M., Newland A. C. : Cancer-associated myasthenic (Eaton-Lambert) syndrome : distribution of abnormality and effect of treatment. J. Neurol. Neurosurg. Psy., 1984, 47, 806-12.
30. Newsom-Davis J., Murray N. M. F. : Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology, 1984, 34, 480-5.
31. Takano H., Tanaka M., Koike R., Nagai H., Arakawa M., Tsuji S. : Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer : correlation with the titer of anti-voltage-gated calcium antibody. Muscle & Nerve, 1994, 17, 1073-5.
32. Graus F., Delatre J. Y. : Immune modulation of paraneoplastic neurologic disorders. Clinic Neurol. Neurosurg., 1995, 97, 112-6.
33. Gracey D. R., Southern P. A. : Respiratory failure in Lambert-Eaton myasthenic syndrome. Chest, 1987, 91, 716-8.
34. Bain P. G., Motomura M., Newsom-Davis J., Misbah S. A., Chapel H. M., Lee M. L., Vincent A., Lang B. : Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology, 1996, 47, 648-83.
35. Dalakas M. C. : Intravenous immune globulin therapy for neurologic diseases. Ann. Intern. Med., 1997, 126, 721-30.
36. Van Der Meché F. G. A., Van Doorn P. A : The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle & Nerve, 1997, 20, 136-47.